FIELD: biotechnology.
SUBSTANCE: method of inhibiting PD-1/PD-L1 signalling pathway in bladder cancer cells by interacting with Mycobacterium bovis BCG-1 vaccine strain. The effect of the invention is achieved by using Mycobacterium bovis BCG-1 vaccine strain. This method can be performed both in vitro and in vivo. The developed method of reducing the expression of PD-L1 in bladder cancer cells can be used in the development of new drugs against bladder cancer, as well as new treatment regimens for bladder cancer.
EFFECT: increasing the effectiveness of adjuvant therapy for bladder cancer.
4 cl, 5 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ABX196 FOR USE IN TREATMENT OF BLADDER CANCER | 2018 |
|
RU2778812C2 |
| COMBINATION OF TASQUINIMOD OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND PD-1 AND/OR PD-L1 INHIBITOR FOR USE AS A MEDICINAL AGENT | 2016 |
|
RU2742373C2 |
| MULTI-SPECIFIC ANTIBODIES INTENDED FOR USE IN TREATMENT OF URINARY TRACT NEOPLASM | 2017 |
|
RU2766358C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO COMPONENTS OF THE SIGNAL PATH PD-1, AND TAXANES | 2014 |
|
RU2719487C2 |
| CONTROL POINT INHIBITOR AND WHOLE-CELL MICROBACTERIA FOR USE IN TREATING ONCOLOGICAL DISEASE | 2014 |
|
RU2719934C2 |
| MONOCLONAL PD-L1 ANTIBODY | 2017 |
|
RU2665790C1 |
| BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS | 2014 |
|
RU2820869C1 |
| TUBERCULOSIS VACCINE WITH IMPROVED STRENGTH | 2004 |
|
RU2342400C2 |
| CONTROL POINT INHIBITOR AND WHOLE MYCOBACTERIAL CELLS FOR USE IN CANCER THERAPY | 2016 |
|
RU2733033C2 |
| BIOMARKERS AND METHODS OF TREATING ASSOCIATED WITH PD-1 AND PD-L1 CONDITIONS | 2014 |
|
RU2701378C2 |
